Maxim initiates Iterum with 'buy'

Iterum Therapeutics

19/01/2024 18:32

** Shares of drug developer Iterum Therapeutics  ITRM.O 
rise ~1.6% to $1.92 
    ** Brokerage Maxim initiates ITRM with "buy" rating, PT at
$7
    ** The price target represents a more than triple upside to
the stock's last close at $1.89
    ** Maxim says it sees the probability of a positive result
for ITRM's trial evaluating a treatment for urinary tract
infections
        ** One of 2 brokerages rate the stock "buy" or higher
and 1 "hold"; their median PT is $7 - LSEG data
    ** Up to last close, stock up 56.2% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))